Patients with BRAF mutations who received adjuvant therapy with dabrafenib and trametinib had a 53% lower risk of 3-year recurrence than those who received placebo.
A new study suggests deficits in cortical bone density and microarchitecture may be responsible.
The benefits of beta-blockers among patients taking statins and ACE inhibitors/ARBs may be limited.
Fibrin clot permeability is commonly used to determine fibrin clot structure.
Drug to be made available through the Cancer Drugs Fund.
Dacomitinib is an irreversible, pan-epidermal growth factor receptor inhibitor.
The study recommends preventive strategies in the newly diagnosed.
Findings from genome-wide association study using TRACK-HD data
Postmarketing surveillance reveals disproportionate rates of depression, aggression, and suicidality.
Data from a large US population study.
Novel vaccines offer reduced hospitalization risk compared with older or no vaccine.
Clinicians should consider benefit-to-risk ratio with olanzapine for patients with mild mania symptoms.
Results from a meta-analysis.
There are still many risks for their concomitant use.
Mortality occurred in 45.8% of men vs 53% of women.
